Drug Discovery@nature.com 30 August 2013

Advertisement Superbugs are on the rise. Take "control" with ATCC multidrug-resistant reference strains, including CRE, ESBL, NDM-1, KPC, MRSA, and VRE. These strains are ideal for the development, verification, and evaluation of rapid detection methods, innovative therapeutic techniques, novel antibiotics, and updated sterility protocols. Visit ATCC online to learn more, and let's stop the threat of superbugs together. www.atcc.org/Superbugs TABLE OF CONTENTS 30 August 2013 News Analysis Research Highlights Research & Reviews Careers Advertisement   Reichert Life Sciences Surface Plasmon Resonance Systems - drug discovery instruments for label-free binding analysis in real time.   Reichert SPR systems generate precise kinetics (on/off rates) and affinity data for lead optimization in drug discovery. The systems are ultra-sensitive, flexible and cost-effective. Reichert systems cited in peer-reviewed abstracts.   ReichertSPR.com Nature Reviews Drug Discovery is on Twitter Advertisement Special section on pharmacogenomics: Recent advances and future directions The special section on pharmacogenomics in the June 2013 issue of Journal of Human Genetics features eight articles on the current state of pharmacogenomics research and its implementation in the clinic.  Take advantage of FREE access to select articles today!   News Top Biotech boom prompts fears of bust doi:10.1038/500513a A spate of successful public offerings has raised ample funding for biotechnology - and anxiety about when the good times will end. Full Text Medical research: Trial unpredictability yields predictable therapy gains doi:10.1038/500395a In decades of clinical-trial data, new treatments are better than standard ones just over half the time. That's as it should be, say Benjamin Djulbegovic and colleagues. Full Text Trials challenging HIV drug doses could usher in huge cost cuts doi:10.1038/nm0813-953 Several dose optimization trials are being pursued in an effort to increase access to HIV drugs in a cost-effective manner while also reducing their toxicity. Full Text SARS-like virus reignites ownership feuds doi:10.1038/nbt0813-671 A coronavirus isolated from a patient in Saudi Arabia is posing questions on IP ownership. Full Text Analysis Top Deep pockets doi:10.1038/scibx.2013.846 The B class of GPCRs is brimming with therapeutic targets, but, so far, development of small molecule drugs has been stymied. New studies reporting the first-ever crystal structures of members of the family could change this. Full Text Novelty in the target landscape of the pharmaceutical industry doi:10.1038/nrd4089 An analysis of the overlap in the drug targets that are being pursued across the industry indicates that more than half of the novel drug targets in current pipelines are being pursued by only one company. Full Text Research Highlights Top Mood disorders: Room for improvement doi:10.1038/nrd4078 Two independent studies shed light on the mechanism of action of commonly prescribed antidepressants and suggest new therapeutic targets. Full Text G protein-coupled receptors: Two landmark class B GPCR structures unveiled doi:10.1038/nrd4082 High-resolution crystal structures of the human corticotropin-releasing factor 1 (CRF1) receptor and the human glucagon receptor are reported in Nature. Full Text Influenza: Viral vector delivers protective antibodies doi:10.1038/nrd4079 Vectored immunoprophylaxis durably protects even immunocompromised mice from illness caused by diverse influenza strains. Full Text Research & Reviews Top Validating therapeutic targets through human genetics doi:10.1038/nrd4051 Many clinical trial failures can be traced back to the limited predictive value of preclinical models of disease. This review discusses how knowledge from human genetics can be used as a tool to more effectively prioritize molecular targets in drug development. Full Text Gene-engineered T cells for cancer therapy doi:10.1038/nrc3565 Adoptive T cell therapy using engineered T cells to improve antitumour responses is showing promise for the treatment of haematological malignancies in particular. This Review discusses the strategies and progress being made to engineer T cells to treat cancer patients. Full Text Bringing genome-wide association findings into clinical use doi:10.1038/nrg3523 Despite the impact of genome-wide association studies (GWASs) on disease genetics, there has been scepticism about their usefulness in clinical translation. This Review highlights pertinent examples in which clinical application has been achieved and considers the wider potential for translation. Full Text Applications of nanotechnology for immunology doi:10.1038/nri3488 This Review describes how the unique properties of different nanostructures can be used to either enhance or to suppress immune responses, and discusses the promise of these strategies for developing more effective immunotherapies. Full Text Drug Discovery JOBS of the week R&D Scientist � Nonclinical Drug Safety (m / f) Boehringer Ingelheim Pharma GmbH & Co. KG Senior Project Manager Drug Discovery and Development (m / f) Akron Molecules GmbH Research Laboratory Head (m / f) Oncology Drug Discovery / In vivo Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG Antibiotic Drug Developer AntibioTx Postdoctoral Fellow in Biomaterials and Drug Delivery Vanderbilt University More Science jobs from Drug Discovery EVENT Venomics: Drug Discovery from Nature�s Deadliest 04.11.13 New York, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.